Patents by Inventor Scott Bethiel

Scott Bethiel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of serine proteases
    Patent number: 8575208
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: November 5, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Robert B. Perni, John Maxwell, Kevin Cottrell, Summer Halas
  • c-MET protein kinase inhibitors
    Patent number: 8232406
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 31, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • C-MET PROTEIN KINASE INHIBITORS
    Publication number: 20110059936
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 10, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, JR., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • c-MET protein kinase inhibitors
    Patent number: 7872031
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: January 18, 2011
    Assignee: Vertex Pharmaceuticals incorporated
    Inventors: David J. Lauffer, Robert J. Davies, Dean Stamos, Alexander Aronov, David D. Deininger, Ronald Grey, Jr., Jinwang Xu, Pan Li, Brian Ledford, Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Kira McGinty
  • Inhibitors of Serine Proteases
    Publication number: 20100272681
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: February 20, 2008
    Publication date: October 28, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Luc Farmer, Randy Scott Bethiel, Dylan Jacobs, Robert B. Perni, John Maxwell, Kevin Cottrell, Summer Halas
  • Inhibitors of IMPDH enzyme
    Patent number: 7087642
    Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: August 8, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Stamos, Martin Trudeau, Scott Bethiel, Steven Ronkin, Michael Badia, Jeffrey Saunders
  • Inhibitors of IMPDH enzyme
    Publication number: 20040029939
    Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
    Type: Application
    Filed: November 4, 2002
    Publication date: February 12, 2004
    Inventors: Dean Stamos, Martin Trudeau, Scott Bethiel, Steven Ronkin, Michael Badia, Jeffrey Saunders
  • Inhibitors of IMPDH enzyme
    Patent number: 6498178
    Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: December 24, 2002
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Dean Stamos, Martin Trudeau, Scott Bethiel, Steven Ronkin, Michael Badia, Jeffrey Saunders
  • Inhibitors of IMPDH enzyme
    Publication number: 20020111378
    Abstract: The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.
    Type: Application
    Filed: September 19, 2001
    Publication date: August 15, 2002
    Inventors: Dean Stamos, Martin Trudeau, Scott Bethiel, Steven Ronkin, Michael Badia, Jeffrey Saunders